drugset / Trial / NCT03769311
Cetuximab in Head and Neck Cancer Patients
Phase 2
Completed
15 enrolled
University of Wisconsin, Madison
American Cancer Society, Inc. · collabNational Institute of Dental and Craniofacial Research (NIDCR) · collab
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial is for participants with head and neck squamous cell carcinoma who are scheduled to have their tumor surgically removed. The study involves obtaining baseline tissue from a clinical biopsy or research biopsy and measurement of circulating tumor cells before surgery to determine whether AXL protein expression pre-treatment correlates to clinical outcomes (change in tumor size) after two doses of cetuximab. The importance of this study is to describe if AXL expression can be used as a biomarker to predict clinical response to cetuximab (CTX) treatment.
Timeline
- Start
- 2019-04-17
- Primary completion
- 2022-03-15
- Completion
- 2022-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |